Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Anavex...
Pharmaceutical
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee...
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Fireside chat scheduled for Wednesday, November 29, 2023, at 2:10 PM ETNEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TG...
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
Media ReleaseCOPENHAGEN, Denmark; November 27, 2023 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) for epcoritamab-bysp for...
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2...
TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023
FORT WORTH, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing...
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment...
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
Conference call today at 8:30 am ETVANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a...
RVL Completes Financial Restructuring
Athyrium Provides Capital to Support Long-Term Growth and Exchanges Outstanding Debt into Equity of Certain Reorganized Entities RVL Pharmaceuticals plc...
Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer
Chimeric Bait Receptor-programmed macrophages show promise for treatment of Non-Hodgkin LymphomaLONDON, UK / ACCESSWIRE / November 27, 2023 / Hemogenyx...
GE HealthCare Showcases More Than 40 Innovations, Including AI-Enabled Imaging Technology Solutions Designed for Precision Care at RSNA23
Booth (#7326) will highlight new product introductions, key innovations, and AI-enabled advancements from the company’s comprehensive portfolio of Imaging, Ultrasound,...
TeleDaaS™ Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations
TeleDaaS revolutionizes radiopharmaceutical research by delivering highly-scalable, clinical-grade dosimetry to accelerate cancer treatment breakthroughsCHICAGO, Nov. 26, 2023 (GLOBE NEWSWIRE) --...
BBS-Bioactive Bone Substitutes: The Notified Body has approved the Company’s quality system
BBS-Bioactive Bone Substitutes Plc, press release, 25 November 2023 at 11.00 a.m. BBS-Bioactive Bone Substitutes Plc ("BBS") has received confirmation...
Positron Corporation Announces Attrius® PET System Sale
Niagara Falls, NY, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular...
Bionxt Solutions Announces Convertible Debenture and Interest Settlement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR...
New Hope for Children: SciSparc’s patented CBD- Enhanced Solution for Autism Spectrum Disorder
TEL AVIV, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical...
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company”...
Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease
WINNIPEG, MB / ACCESSWIRE / November 23, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused...
iZafe Group and Atea Sweden Have Entered into an Agreement with VGR in the Field of Welfare Technology
STOCKHOLM, SE / ACCESSWIRE / November 23, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB ("iZafe Group") announces that the...
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion...